Evelo Biosciences Inc
NASDAQ:EVLO
Income Statement
Earnings Waterfall
Evelo Biosciences Inc
Revenue
|
0
USD
|
Operating Expenses
|
-74.3m
USD
|
Operating Income
|
-74.3m
USD
|
Other Expenses
|
-8m
USD
|
Net Income
|
-82.3m
USD
|
Income Statement
Evelo Biosciences Inc
Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
Operating Income | |||||||||||||||||||||||||
Operating Expenses |
(28)
|
(33)
|
(42)
|
(50)
|
(58)
|
(68)
|
(75)
|
(80)
|
(86)
|
(89)
|
(88)
|
(86)
|
(92)
|
(96)
|
(104)
|
(116)
|
(115)
|
(120)
|
(119)
|
(115)
|
(108)
|
(105)
|
(93)
|
(74)
|
|
Selling, General & Administrative |
(8)
|
(9)
|
(13)
|
(16)
|
(18)
|
(20)
|
(21)
|
(22)
|
(23)
|
(24)
|
(23)
|
(22)
|
(22)
|
(22)
|
(24)
|
(29)
|
(32)
|
(35)
|
(37)
|
(34)
|
(30)
|
(28)
|
(24)
|
(21)
|
|
Research & Development |
(20)
|
(23)
|
(29)
|
(35)
|
(40)
|
(48)
|
(54)
|
(58)
|
(63)
|
(65)
|
(65)
|
(64)
|
(70)
|
(74)
|
(79)
|
(87)
|
(84)
|
(81)
|
(82)
|
(81)
|
(79)
|
(77)
|
(69)
|
(53)
|
|
Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(3)
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Operating Income |
(28)
N/A
|
(33)
-19%
|
(42)
-28%
|
(50)
-20%
|
(58)
-16%
|
(68)
-18%
|
(75)
-9%
|
(80)
-7%
|
(86)
-8%
|
(89)
-3%
|
(88)
+1%
|
(86)
+2%
|
(92)
-6%
|
(96)
-5%
|
(104)
-8%
|
(116)
-12%
|
(115)
+1%
|
(120)
-4%
|
(119)
+1%
|
(115)
+3%
|
(108)
+6%
|
(105)
+3%
|
(93)
+12%
|
(74)
+20%
|
|
Pre-Tax Income | |||||||||||||||||||||||||
Interest Income Expense |
(0)
|
(0)
|
0
|
1
|
2
|
2
|
2
|
2
|
1
|
0
|
(1)
|
(1)
|
(2)
|
(3)
|
(3)
|
(3)
|
(4)
|
(4)
|
(4)
|
(4)
|
(5)
|
(4)
|
(4)
|
(5)
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(3)
|
(3)
|
(3)
|
0
|
0
|
0
|
(1)
|
0
|
(2)
|
(3)
|
|
Total Other Income |
(0)
|
(0)
|
(1)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
1
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
1
|
|
Pre-Tax Income |
(28)
N/A
|
(33)
-18%
|
(42)
-26%
|
(50)
-18%
|
(57)
-15%
|
(67)
-17%
|
(73)
-9%
|
(78)
-8%
|
(85)
-9%
|
(88)
-3%
|
(88)
+0%
|
(87)
+1%
|
(93)
-7%
|
(98)
-5%
|
(109)
-11%
|
(122)
-12%
|
(122)
+0%
|
(123)
-1%
|
(122)
+1%
|
(119)
+3%
|
(114)
+5%
|
(109)
+4%
|
(100)
+9%
|
(81)
+18%
|
|
Net Income | |||||||||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(0)
|
(0)
|
(1)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
|
Income from Continuing Operations |
(28)
|
(33)
|
(42)
|
(50)
|
(57)
|
(67)
|
(73)
|
(78)
|
(85)
|
(88)
|
(88)
|
(87)
|
(94)
|
(99)
|
(110)
|
(123)
|
(122)
|
(124)
|
(123)
|
(120)
|
(115)
|
(110)
|
(101)
|
(82)
|
|
Net Income (Common) |
(34)
N/A
|
(40)
-19%
|
(49)
-22%
|
(55)
-12%
|
(61)
-10%
|
(68)
-12%
|
(73)
-6%
|
(78)
-8%
|
(85)
-9%
|
(88)
-3%
|
(88)
+0%
|
(87)
+1%
|
(94)
-7%
|
(99)
-5%
|
(110)
-11%
|
(123)
-12%
|
(122)
+0%
|
(124)
-1%
|
(123)
+1%
|
(120)
+3%
|
(115)
+4%
|
(110)
+4%
|
(101)
+9%
|
(82)
+18%
|
|
EPS (Diluted) |
-21.46
N/A
|
-25.44
-19%
|
-31.04
-22%
|
-34.79
-12%
|
-38.28
-10%
|
-42.66
-11%
|
-45.33
-6%
|
-48.94
-8%
|
-53.41
-9%
|
-54.78
-3%
|
-53.93
+2%
|
-37.75
+30%
|
-47.54
-26%
|
-38.45
+19%
|
-41.11
-7%
|
-45.91
-12%
|
-46.1
0%
|
-46.2
0%
|
-32.4
+30%
|
-22.15
+32%
|
-26.28
-19%
|
-19.81
+25%
|
-18.01
+9%
|
-4.73
+74%
|